Appendix 4E and 2026 Annual Report
Filed with ASX · · 70 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax, which is an improvement compared to the previous year. The company is advancing the development of its proprietary insecticides, Flavocide and Qcide, with significant progress in regulatory studies and commercial partnerships. Bio-Gene also secured funding to support its ongoing product development and commercialization efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Bio-Gene Technology Ltd. on 6ix
Story so far
Earlier from Bio-Gene Technology
- Results of Placement
- Sumitomo & Nakashima to launch Qcide products in Japan
- Regulatory Development of Flavocide
- Appendix 4D and Half-Year Accounts 31 December 2025
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Bio-Gene Technology into a list and get an email when it puts out news.
Follow Bio-Gene Technology